Abstract: ObjectiveTo explore the expressions and clinical significance of matrix metalloproteinase9 (MMP9) and tissue inhibitor of metalloproteinase1 (TIMP1) in renal carcinoma. MethodsA total of 45 patients with renal carcinoma received treatment at our hospital from January 2015 to January 2017 were enrolled as observation group, and 40 healthy subjects in the same period were enrolled as control group. The expressions of MMP9 and TIMP1 in observation group and control group were tested and compared by enzymelinked immunosorbent assay. The relationship between MMP9 and TIMP1 and their correlations with the clinical pathological features were analyzed. ResultsThe serum levels of MMP9  in observation group were higher than those in control group, and the differences were significantly significant［(461.7±53.6) pg/ml vs. (142.9±31.7) pg/ml; t=32.840, P<0.001］, TIMP1 ［(387.9±11.8) pg/ml vs.(136.5±21.8) pg/ml; t=13.290, P<0.001］ and MMP9/TIMP1 ［(1.2±0.2) vs. (1.1±0.1); t=3.640, P<0.001］ . Correlation analysis showed that the serum expression level of MMP9 had significantly positive correlation with TIMP1 for patients in observation group (r=0.847, P<0.001). The serum expression levels of MMP9 and TIMP1 for patients in observation group were related to the lymph node state (t=2.657, P=0.011; t=4.420, P<0.001) and primary tumor staging (t=6.200, P<0.001; t=5.042, P<0.001), but they were not related to pathological type (t=1.130, P=0.265; t=0.109, P=0.914). ConclusionThe peripheral blood levels of MMP9 and TIMP1 are increased in patients with renal carcinoma, and they are associated with the progression of disease, which can be used to evaluate the progress of disease.

Key words: Kidney neoplasms, Matrix metalloproteinase 9, Lymphatic metastasis, Tissue inhibitor of metalloproteinase-1